What are Insulin Receptor antibodies?
Anti-Insulin Receptor antibodies are immunoglobulins that specifically recognize and bind the Insulin Receptor, encoded by the INSR gene in humans. In research applications, these antibodies are used to detect the Insulin Receptor in tissue samples, cell lysates, and cultured cells. The Insulin Receptor is a receptor tyrosine kinase that, upon insulin binding, phosphorylates intracellular substrates such as IRS1 through IRS4, initiating signaling cascades that regulate glucose uptake, metabolism, and cell growth. Because impaired insulin receptor signaling underlies insulin resistance and type 2 diabetes, this receptor remains a central target in metabolic disease research.
Catalog highlights and purchasing considerations
About the Biocompare Insulin Receptor antibody catalog
The Biocompare antibody search tool lists Insulin Receptor antibodies from a wide range of suppliers, with western blot, immunohistochemistry, and ELISA among the most common validated applications. Listings may also appear under the gene symbol INSR or the alternate designation CD220, along with phospho-specific variants targeting distinct regulatory tyrosine residues. Several Insulin Receptor antibodies mentioned here have been cited across a range of metabolic research, including studies on a blood-brain barrier tissue model for lipid nanoparticle delivery and integrin-linked kinase regulation of hepatic fat accumulation through CD36 localization.
Considerations when choosing an Insulin Receptor antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.